Form 4: Revolution Medicines GC Sells Shares Under 10b5-1 Plan

Revolution Medicines General Counsel Jeff Cislini exercised options and sold 13,388 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Jeff Cislini, General Counsel of Revolution Medicines, Inc. (RVMD), executed a stock transaction on November 18, 2025.
• He exercised stock options to acquire 13,388 shares of common stock at an exercise price of $42.45 per share.
• Concurrently, he sold 13,388 shares of common stock at a weighted average price of $70.138 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025.
• Following these transactions, Cislini beneficially owns 50,425 shares of common stock, which includes 43,910 restricted stock units.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction under a 10b5-1 plan, which is a common practice for executives to manage their equity holdings. It does not inherently signal positive or negative company performance.

Positives

• The sale was executed at a price significantly higher than the exercise price ($70.138 vs. $42.45), indicating a profitable transaction for the insider.
• The transaction was conducted under a pre-arranged 10b5-1 trading plan, suggesting a planned liquidity event rather than a reaction to new, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.

Future Outlook

N/A. This filing reports a past transaction and does not provide forward-looking statements or guidance.

Industry Context

This is a routine insider transaction for a biotechnology company executive. Such transactions are common for executives managing their personal portfolios and liquidity, especially when executed under pre-arranged 10b5-1 plans, which are designed to avoid accusations of trading on material non-public information.

Comparison to Industry Standards

• N/A. This filing details an individual insider transaction, not company performance metrics that can be directly compared to industry benchmarks or specific competitor results.

Stakeholder Impact

• Shareholders: The sale by a General Counsel slightly reduces insider ownership, which could be viewed neutrally or slightly negatively by some, though the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction by Revolution Medicines' General Counsel, Jeff Cislini, involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. Such transactions are common for executives managing personal finances and do not typically reflect new material information about the company's operational performance or future prospects. Therefore, this specific filing alone does not provide a basis for a change in investment recommendation; a 'hold' stance is maintained pending further fundamental analysis of the company's financial results and strategic developments.

Keywords

Revolution Medicines, RVMD, Jeff Cislini, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, 10b5-1 Plan, General Counsel